Do you want to volunteer for Clinical Trials? Register now

Volunteer for Clinical Trials

Have you ever thought about taking part in a Medical Trial? By registering your details with MedTrials.co.uk, we are able to send your details directly to companies who are looking for volunteers to take part in their medical research studies.

Information about you is kept on a register that CROs, Pharmaceutical companies and Clinical Investigators can access to contact you regarding individual studies.

Register now >

Clinical Trials Phases and Studies

Pre-clinical studies involve in vitro (i.e., test tube or laboratory) studies and trials on animal populations. Wide ranging dosages of the compounds are introduced to the animal subjects or to an in-vitro substrate in order to obtain preliminary efficacy and pharmacokinetic information and to assist pharmaceutical companies in decisions regarding further development of the test compound, test item or test article.

Phase 0

Phase 0 is a recent designation for exploratory, first-in-human trials conducted in accordance with the Food and Drug Administration’s (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies. Phase 0 trials are designed to expedite the development of promising therapeutic or imaging agents by establishing very early on whether the agent behaves in human subjects as was anticipated from preclinical studies. Distinctive features of Phase 0 trials include the administration of single subtherapeutic doses of investigational agent to a small number of subjects (10 to 15) to gather preliminary data on the agent’s pharmacokinetic and pharmacodynamic properties and mechanism of action.

Phase I (one)

Phase I trials are the first-stage of testing in human subjects. Normally a small (20-80) group of healthy volunteers will be selected. This phase includes trials designed to assess the safety (Pharmacovigilance), tolerability, pharmacokinetics, and pharmacodynamics of a therapy. These trials are almost always conducted in an inpatient clinic, where the subject can be observed by full-time medical staff. The subject is usually observed until several half-lives of the drug have passed. Phase I trials also normally include dose-ranging studies so that doses for clinical use can be refined. The tested range of doses will usually be a small fraction of the dose that causes harm in animal testing. Phase I trials most often include healthy volunteers, however there are some circumstances when patients are used, such as with oncology (cancer) and HIV drug trials. In Phase I trials of new cancer drugs, for example, patients with advanced (metastatic) cancer are used. These trials are usually offered to patients who have had other types of therapy and who have few, if any, other treatment choices.

There are different kinds of Phase I trials:

SAD

Single Ascending Dose studies are those in which small groups of patients are given a single dose of the drug while they are observed and tested for a period of time. If they do not exhibit any adverse side effects, and the pharmacokinetic data is roughly in line with predicted safe values, the dose is escalated, and a new group of patients is then given a higher dose. This is continued until pre-calculated pharmacokinetic safety levels are reached, or intolerable side effects start showing up (at which point the drug is said to have reached the Maximum tolerated dose (MTD) ).

MAD

Multiple Ascending Dose studies are conducted to better understand the pharmacokinetics & pharmacodynamics of multiple doses of the drug. In these studies, a group of patients receives multiple low doses of the drug, whilst samples (of blood, and other fluids) are collected at various time points and analyzed to understand how the drug is processed within the body. The dose is subsequently escalated for further groups, up to a predetermined level.

Food effect

A short trial designed to investigate any differences in absorption caused by eating pre-dose, and its effect on the pharmacokinetic profile. These studies are usually run as a crossover study, with volunteers given two identical doses of the drug on different occasions; one while fasted, and one after being fed.

Phase II (two)

Once the initial safety of the therapy has been confirmed in Phase I trials, Phase II trials are performed on larger groups (20-300) and are designed to assess the activity of the therapy, as well as to continue Phase I safety assessments in a larger group of volunteers and patients. The development process for a new drug commonly fails during Phase II trials due to the discovery of poor activity or toxic effects.

Phase II studies are sometimes divided into Phase IIA and Phase IIB. Phase IIA is specifically designed to assess dosing requirements, whereas Phase IIB is specifically designed to study efficacy.

Some trials combine Phase I and Phase II into a single trial, monitoring both efficacy and toxicity.

Trial design

Some phase II trials are designed as case series, demonstrating safety and activity in a selected group of patients. Other phase II trials are designed as randomized Clinical Trials, complete with a treatment arm and a comparison arm. Randomized phase II trials have far fewer patients than randomized phase III trial.

Phase III (three)

Phase III studies are randomized controlled trials on large patient groups (300–3,000 or more depending upon the condition) and are aimed at being the definitive assessment of the efficacy of the new therapy, in comparison with current ‘Gold Standard’ treatment. Phase III trials are the most expensive, time-consuming and difficult trials to design and run, especially in therapies for chronic conditions. Once a drug has proven satisfactory over Phase III trials, the trial results are usually combined into a large document containing a comprehensive description of the methods and results of human and animal studies, manufacturing procedures, formulation details, and shelf life. This collection of information makes up the “regulatory submission” that is provided for review to various regulatory authorities in different countries for marketing approval.

It is also common practice with many drugs whose approval is pending, that certain phase III trials will continue. This typically serves to provide lifesaving products after involvement in a Clinical Trial until the marketed product can be obtained. Other reasons for performing trials at this stage include attempts at “label expansion” to prove additional efficacy for uses beyond the original use for which the drug was designed, to obtain additional safety data, or to support marketing claims. Studies in this phase are by some companies categorised as “Phase IIIB studies.”

While not required in all studies, it is typically expected that there be at least two successful phase III trials, proving a drug’s safety and efficacy, for approval from the standard regulatory agencies (FDA, TGA, EMEA, etc.). Though the current trend in recent months seems to be a move toward adaptive (live, changing) studies to expedite the process, there are no formal regulations for these trials in the pharmaceutical industry as of yet.

Phase IV (four)

Phase IV trials involve the post-launch safety surveillance and ongoing technical support of a drug. Phase IV studies may be mandated by regulatory authorities or may be undertaken by the sponsoring company for competitive or other reasons (for example, the drug may not have been tested for interactions with other drugs, or on certain population groups such as pregnant women, who are unlikely to subject themselves to trials). Post-launch safety surveillance is designed to detect any rare or long-term adverse effects over a much larger patient population and timescale than was possible during the initial Clinical Trials. Such adverse effects detected by Phase IV trials may result in the withdrawal or restriction of a drug – recent examples include cerivastatin (brand names Baycol and Lipobay), troglitazone (Rezulin) and rofecoxib (Vioxx).

Placebos

If there is no standard treatment, patients taking part in a trial may be given a dummy drug, which looks like the drug being tested. This dummy drug is called a placebo. Placebos are used because sometimes people get better without treatment.

In some trials where a new treatment is being compared with the standard treatment, placebos are also used. This is usually because the treatments can be easily distinguished by the appearance of the drug being supplied and the patient could become aware of what they are taking. In this case two placebos are used, one made to look like each of the drugs and each person receives one of these placebos and one real drug.

If you are asked to take part in a placebo controlled trial, neither you nor your doctor will know whether you are taking a placebo or the new drug.

Adjuvant studies

Adjuvant studies are conducted to determine if additional therapy will improve the chance for cure in patients at risk for the cancer coming back after surgical removal of all visible disease. An example is a study for patients with large bowel cancer. The standard therapy for large bowel cancer is surgery. An adjuvant study could be run in which one group of patients with large bowel cancer received surgery and the other group received surgery and then chemotherapy. If the study shows that surgery plus chemotherapy is better than surgery alone, surgery plus chemotherapy will become the new, standard therapy. Adjuvant studies progress through phase I, II, and III trials like other treatment studies.

Neoadjuvant studies

Neoadjuvant treatment is given first to try to reduce the cancer to a size where standard therapy is effective. For example, the standard therapy for head and neck cancer is radiotherapy and/or surgery. Sometimes the cancer is too large to safely treat by either of these methods. The chemotherapy may make the tumor shrink to a size that can be treated with radiotherapy or that can be removed surgically. Neoadjuvant studies progress through phase I, II, and III trials like other treatment studies.

Supportive care studies

Clinical Trials also try to find better ways of caring for the side effects caused by cancer treatment (such as nausea and vomiting) and the side effects of the cancer itself (such as pain or sleeplessness). Some supportive care studies use drugs to treat side effects, and such studies will have phases (phase I, II, or III) like cancer therapy Clinical Trials. Other studies look at whether support groups help ease the discomfort of the patient. Supportive care studies sometimes try to find better ways to help the families of patients with cancer cope with the illness of a loved-one.

Prevention and early detection studies

Often people in prevention studies are considered likely to develop cancer (high risk) because several family members have related cancers. Prevention studies usually compare a group of people that receive no special treatment to a group that is given a drug or a change in diet to try to prevent cancer from developing. People in both groups are contacted for many years to see if there is a difference in how many of them get cancer. Early detection studies assess methods of screening people for cancer to try to find the cancer when it is still very small. If the cancer can be found when it is small, the cancer may be more easily treated, increasing the chance for survival. These methods may use x-rays, blood tests, or touch (among others) to find cancer. Early detection studies may or may not run over many years.

Group C and Treatment Referral Center studies

These types of studies make drugs available to some cancer doctors. These drugs have been through Clinical Trials, have been shown to work for some tumors, and may soon be approved by the Food and Drug Administration for sale. Group C drugs can be used by a wider group of doctors than drugs used in either modified Group C or Treatment Referral Center studies. Patients who receive drugs by any of these means are checked regularly by their doctor as if they were on a Clinical Trial.

Useful Medical Trial information

News

Yoga just as good as physical therapy for low back pain

A new trial establishes that yoga is “statistically as effective” as physical therapy for treating chronic low back pain. Powered by WPeMatico

more >

Study questions whether mistaken antibodies led cancer research down a 20-year dead end

For nearly two decades researchers have sought a way to target an estrogen receptor in the hope they could improve breast cancer survival, but an article published in Nature Communications contends… Powered by WPeMatico

more >

Plant compound ‘much more effective’ than traditional anti-HIV drug

New research finds a plant extract that is much more effective at inhibiting HIV’s ability to infect healthy cells than the traditional AZT. Powered by WPeMatico

more >

LifeArc, previously MRC Technology, to invest £500M

LifeArc, the U.K. medical research charity previously known as MRC Technology, announced plans to improve the lives of patients suffering from diseases that present the greatest challenges to medical research. By investing up to £500 million over the next five years, LifeArc will seek to generate, fund and champion innovations in antimicrobials, neuroscience, personalized oncology […]

more >

Parexel, Sanofi partner on wearables

Parexel International, a global biopharmaceutical services organization, announced a collaboration with Sanofi to advance the use of wearable devices to transform the collection of data in clinical trials. Wearables have the potential to address several challenges related to clinical trials and improve execution by increasing patients’ ability to participate, driving patient engagement, and creating more […]

more >

InSync named Top 10 Fastest Growing EMR Solution Provider

InSync Healthcare Solutions, a provider of cloud-based healthcare solutions, announced the company was recognized by Insights Success as a “Top 10 Fastest Growing EMR Solution Provider.” The list features a wide variety of healthcare technology companies; however, Insights Success noted, “InSync’s commitment to transforming efficient patient care separates the Tampa-based company from the rest of […]

more >